bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract LB014: Carbon monoxide induced PERK regulated autophagy reprograms anti-tumor T cells with robust immunometabolic phenotype
Authors: Chakraborty Paramita , Parikh Rasesh Y. , Choi Seungho , Mehrotra Meenal , Maldonado Eduardo N. , Wang Hongjun , Diehl J. Alan , Gangaraju Vamsi K. , Mehrotra Shikhar 
Published: June 2022

Abstract
Mitochondria and Endoplasmic reticulum (ER) share structural and functional networks to maintain cellular homeostasis and activate well-orchestrated signaling processes to shape cells' fate and function. While persistent ER stress (ERS) response leads to mitochondrial collapse, moderate ERS condition drives mitochondrial biogenesis and function. So far, various strategies have been tested to enhance the mitochondrial function in T cells to improve their anti-tumor potential. However, strategies targeting ER-Mitochondria crosstalk (by employing moderate ERS condition) to boost the anti-tumor T cell function have not been exploited yet. Thus, in the present study, we used carbon monoxide (CO), a short-lived gaseous molecule, to test if engaging moderate ERS conditions can improve T cells mitochondrial biogenesis, function, and anti-tumor therapeutic efficacy. Using melanoma antigen gp100 reactive T cells, we identify that CO induced transient activation of ERS sensor ‘protein kinase R-like endoplasmic reticulum kinase (PERK)’ dramatically increase anti-tumor T cell function. Furthermore, mechanistically we found that CO-induced PERK activation temporarily halts protein translation and induces protective autophagy (that includes mitophagy). To get further insight into how CO treatment kinetically regulates autophagic activity in T cells, we used LC3-GFP to differentiate between the cells that prepare themselves to undergo active autophagy (LC3-GFPpos) and those that fail to enter into the process (LC3-GFPneg). Using Ag-specific LC3-GFP expressing T cells, we demonstrate that LC3-GFPpos T cells show robust anti-tumor potential. Moreover, LC3-GFPneg shows a T regulatory-like phenotype, harbors dysfunctional mitochondria, and accumulates abnormal metabolite content. These anomalous ratios of metabolites render the cells with a hypermethylated state and distinct epigenetic profile limiting their anti-tumor activity. Overall, this preclinical data highlights that ERS-mediated activation of autophagy pathways modifies the mitochondrial function and epigenetically reprogram the T cells towards a superior anti-tumor phenotype and can be therapeutically translated to achieve robust tumor control in adoptive transfer therapies.
Citation Format: Paramita Chakraborty, Rasesh Y. Parikh, Seungho Choi, Meenal Mehrotra, Eduardo N. Maldonado, Hongjun Wang, J. Alan Diehl, Vamsi K. Gangaraju, Shikhar Mehrotra. Carbon monoxide induced PERK regulated autophagy reprograms anti-tumor T cells with robust immunometabolic phenotype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB014.
Abstract LB032: CXCR7 drives prostate cancer growth through AURKA activation
Authors: Gritsina Galina , Lin Zhuoyuan , Fong Ka Wing , Lu Xiaodong , Zhao Changsheng , Yu Jindan 
Published: June 2022

Abstract
Prostate cancer (PCa) is the most commonly diagnosed cancer among males in the United States. The mainstay treatment for metastatic PCa patients is androgen-deprivation therapies, including high-affinity androgen receptor antagonists, such as enzalutamide. Unfortunately, most patients develop resistance and relapse with castration-resistant PCa (CRPC). We have previously reported up-regulation of CXCR7, an atypical chemokine receptor, in CRPC. CXCR7 interacts with beta-arrestin (ARRB2), a cytoplasmic scaffold protein, and translocates to the cytoplasm to induce signal transduction and PCa progression. However, much remains to be known regarding CXCR7-driven downstream signaling and its therapeutic targeting in advanced PCa. To unveil CXCR7-downstream signaling, we utilized RNA-seq to profile gene expression. Gene ontology analyses revealed remarkable enrichment of CXCR7-regulated genes in G2/M cell cycle progression. Comprehensive phospho-proteomics analysis of CXCR7-knockdown PCa cells showed markedly reduced phosphorylation of AURKA substrates. AURKA, a serine/threonine-protein kinase, is a key regulator of mitosis and G2/M progression and is frequently upregulated in CRPC and the late-stage neuroendocrine PCa (NEPC). Activated AURKA experiences autophosphorylation and phosphorylates downstream substrates, e.g., TACC3, that mediate proper cell division. Immunoblotting confirmed that CXCR7 depletion reduces phosphorylation of AURKA and TACC3. Co-immunoprecipitation revealed protein-protein interaction between CXCR7 and AURKA, which is mediated by ARRB2. Accordingly, ARRB2-knockdown similarly inhibits AURKA phosphorylation and arrests cell proliferation. Immunofluorescence coupled with confocal imaging demonstrated that CXCR7 is packed into clathrin-coated vesicles and locates in the plasma membrane, cytoplasm, and perinuclear Golgi complex, which surrounds the centrosomal AURKA and ARRB2. We found that CXCR7 translocates to the Golgi complex along microtubule-dependent trafficking. Finally, we found that pharmacological inhibitors of AURKA abolish CXCR7-driven PCa cell proliferation in vitro and tumor growth in vivo.
Conclusions: Our results describe for the first time that the CXCR7-ARRB2 complex interacts with AURKA and promotes its activation. Our data suggest that AURKA-targeting is a promising therapeutic strategy for CRPC and NEPC with CXCR7 up-regulation.
Citation Format: Galina Gritsina, Zhuoyuan Lin, Ka Wing Fong, Xiaodong Lu, Changsheng Zhao, Jindan Yu. CXCR7 drives prostate cancer growth through AURKA activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB032.
Abstract LB054: Prometastatic effect of ATX derived from alveolar type II pneumocytes and B16F10 melanoma cells
Authors: Dacheux Melanie A. , Lee Sue Chin , Shin Yoojin , Norman Derek D. , Lin Kuan-Hung , Tigyi Gabor J. 
Published: June 2022

Abstract
Although metastasis is the principal cause of cancer-related deaths, the molecular aspects of the role of stromal cells in the establishment of the metastatic niche remain poorly understood. One of the most prevalent sites for cancer metastasis is the lungs. According to recent research, lung stromal cells such as bronchial epithelial cells and resident macrophages secrete autotaxin (ATX), an enzyme with lysophospholipase D activity that promotes cancer progression. In fact, several studies have shown that many cell types in the lung stroma could potentially provide a rich source of ATX in diseases. In the present study, we sought to determine whether ATX derived from alveolar type II epithelial (ATII) pneumocytes could modulate the progression of lung metastasis, which has not been evaluated previously. To accomplish this, we used the B16-F10 syngeneic melanoma model, which readily metastasize to the lungs when injected intravenously. Because B16-F10 cells express high levels of ATX, we used the CRISPR-Cas9 technology to knockout (KO) ATX in B16-F10 cells, eliminating the contribution of tumor-derived ATX in lung metastasis. Next, we used the inducible Cre/lox system (Sftpc-CreERT2/Enpp2fl/fl) to generate conditional KO mice in which ATX is specifically deleted in ATII cells (i.e. Sftpc-KO). Injection of ATX-KO B16-F10 cells into Sftpc-KO or Sftpc-WT control littermates allows us to investigate the specific contribution of ATII-derived ATX in lung metastasis. We found that targeted KO of ATX in ATII cells significantly reduced the metastatic burden of ATX-KO B16-F10 cells by 30% compared to Sftpc-WT mice (unpaired t-test, p=0.0283), suggesting that ATX derived from ATII cells could affect the metastatic progression. We detected upregulated levels of cytokines such as IFNγ (unpaired t-test, p&lt;0.0001) and TNFα (unpaired t-test, p=0.0003), which could favor the increase in infiltrating CD8+-T cells observed in the tumor regions of Sftpc-KO mice. Taken together, our results highlight the contribution of host ATII cells as a stromal source of ATX in the progression of melanoma lung metastasis.
Citation Format: Melanie A. Dacheux, Sue Chin Lee, Yoojin Shin, Derek D. Norman, Kuan-Hung Lin, Gabor J. Tigyi. Prometastatic effect of ATX derived from alveolar type II pneumocytes and B16F10 melanoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB054.
Abstract LB082: Genome-wide CRISPR activation screen identifies PRRX2 as an enzalutamide resistance gene in prostate cancer
Authors: Rodriguez Yara R. , Unno Kenji , Truica Mihai , Chalmers Zachary R. , Yoo Young A , Vatapalli Rajita , Sagar Vinay , Yu Jindan , Lysy Barbara , Han Huiying , Abdulkadir Sarki A. 
Published: June 2022

Abstract
Androgen receptor pathway inhibitors are the mainstay treatment for advanced prostate cancer, but resistance is common. Here, we used a CRISPR activation screen to identify genes that promote enzalutamide resistance in the metastatic castration-sensitive prostate cancer cell line LNCaP. We found that activation of the TGF-β target gene, PRRX2, promoted enzalutamide resistance. PRRX2 expression is highest in double negative prostate cancer (DNPC) patients and a PRRX2-related gene signature identified a subset of DNPC patients with lower overall survival. PRRX2 expressing cells showed alterations in the CDK4/6/Rb/E2F and BCL2 pathways. Accordingly, CDK4/6 and BCL2 inhibitors sensitized PRRX2-expressing enzalutamide-resistant tumors to enzalutamide. High PRRX2 expression/signature in prostate cancer merit investigation as markers of enzalutamide resistance that could be reversed with CDK4/6 and BCL2 inhibitors.
Citation Format: Yara R. Rodriguez, Kenji Unno, Mihai Truica, Zachary R. Chalmers, Young A Yoo, Rajita Vatapalli, Vinay Sagar, Jindan Yu, Barbara Lysy, Huiying Han, Sarki A. Abdulkadir. Genome-wide CRISPR activation screen identifies PRRX2 as an enzalutamide resistance gene in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB082.
Abstract LB096: EGFR-dependent inflammation as a driver of breast cancer
Authors: Escoto Angelica 
Published: June 2022

Abstract
Triple Negative Breast Cancer (TNBC) is one of the most aggressive and metastatic subtypes of hormone receptor negative breast cancers. Evidence supports that most patients with TNBC overexpress the Epidermal Growth Factor Receptor (EGFR), yet its role in driving the disease remains unclear. Therapies have been developed to target EGFR, but EGFR-targeted antibodies and tyrosine kinase inhibitors fail to work effectively in breast cancer patients. A possible explanation is that in addition to its canonical function at the membrane, EGFR has a non-canonical function where it can undergo retrograde trafficking to the nucleus, making it resistant to antibody-based therapeutics. Once in the nucleus, EGFR is known to function as a transcriptional cofactor for STAT3, STAT5, and E2F1, thereby regulating the expression of genes that promote inflammation and cell proliferation. Via RNA-Seq analysis, we demonstrate that EGFR can regulate different subsets of genes depending on its canonical signaling activity or nuclear role. Our goal is to understand and distinguish this difference in regulation to assess how EGFR affects inflammation. We hypothesize that EGFR is modifying inflammation differently depending on its canonical or non-canonical role, thereby driving disease progression in multiple ways. We have found that canonical EGFR can induce interleukin 8 while nuclear EGFR can repress interleukin 6 through the use of either kinase inhibitors (IL8) or blocking nuclear translocation of EGFR (IL6). Correlated with these changes are alterations in growth and inflammatory profiles in both a triple negative inflammatory mouse model and an EGFR-driven breast cancer mouse model. We are now investigating the role of nuclear-EGFR-dependent inflammation in driving tumor progression. Understanding the different mechanisms by which EGFR modifies inflammation and the tumor microenvironment would allow us to develop more specific targets for patients with TNBC.
Citation Format: Angelica Escoto. EGFR-dependent inflammation as a driver of breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB096.
Abstract LB128: Oncolytic HSV-P10 and effects on metabolism as potential therapy for treatment of glioblastoma
Authors: Mullarkey Matthew P. , Sahu Upasana , Hong Bangxing , Kaur Balveen 
Published: June 2022

Abstract
Glioblastoma is an aggressive tumor of the central nervous system associated with a very poor prognosis even with surgery and chemoradiation. We have previously developed an oHSV that encodes for PTENα (HSV-P10) and stimulates anti-tumor immunity. This virus is currently licensed by and is being developed by Mesoblast to evaluate safety and efficacy in patients. To understand the effect of PTENα on tumor cell responses to oHSV therapy we performed RNA sequencing of primary GBM cells infected with control or oHSV-P10. We identified a dysregulation of glycolysis in cells infected with oHSV-P10 relative to control oHSV. Since cancer cells rely heavily on glycolysis for energy production (Warburg effect) the impact of PTENα on metabolic switch was significant. RNA sequencing PCR and western blot analysis showed a significant reduction in cellular Hexokinase II expression and downregulation of HIF-1α in HSV-P10 infected cells. Consistent with the function of HIF1 and hexokinase in driving glycolysis we also observed a significant reduction in glucose uptake and lactate release: implying a reduction in glycolysis in cells after being treated with oHSV-P10. Thus, cellular energetics of HSV-P10 infected cells was directed away from glycolysis relative to HSVQ infected cells. Consistent with this we observed increased, oxidative phosphorylation, production of reactive oxidative species and ATP production. Many cancers, including Glioblastoma are known to utilize the glutamine as a substrate for energy production through its entry into the TCA cycle. Blocking this shows a significant decrease in cell viability and ATP production when combined with HSV-P10. These results indicate that combination of HSV-P10 with radiation has a significant therapeutic potential and should be tested in patients for safety and efficacy.
Citation Format: Matthew P. Mullarkey, Upasana Sahu, Bangxing Hong, Balveen Kaur. Oncolytic HSV-P10 and effects on metabolism as potential therapy for treatment of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB128.
Abstract LB129: Analysis of KRAS wildtype pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
Authors: Topham James , Tsang Erica , Karasinska Joanna , Metcalfe Andrew , Ali Hassan , Kalloger Steve , Csizmok Veronika , Williamson Laura , Titmuss Emma , Wong Hui-Li , Moore Richard , Mungall Andrew , Loree Jonathan , Bathe Oliver , Tang Patricia , Goodwin Rachel , Laskin Janessa , Marra Marco , Jones Steven , Schaeffer David , Renouf Daniel 
Published: June 2022

Abstract
Introduction
Oncogenic KRAS mutations are absent in 10% of patients with pancreatic ductal adenocarcinoma (PDAC) and may represent a subgroup of PDAC with therapy options beyond standard-of-care chemotherapy. While distinct gene fusions have been implicated in KRAS wildtype (wt) PDAC, other traits unique to KRAS wt PDAC remain unexplored.
Methods
Patients with treatment-naive metastatic PDAC (n=63) received matched tumor/normal whole-genome and RNA sequencing and clinical follow-up as part of the PanGen trial (NCT02869802). Clinical data and mutation, gene fusion and copy alteration frequency was compared between KRAS wt (n=9) and mutant (n=54) groups. Metastatic colorectal adenocarcinoma and cholangiocarcinoma samples from the POG trial (NCT02155621) were incorporated for sequencing-based comparison.
Results
KRAS wt tumors showed lower frequency of TP53 SNV/indels (p=0.01) and distinct amplifications affecting chr1q genes NR5A2 (p=9.0e-4), MPC2 (p=0.002) and MCL1 (p=0.02) and chr8q gene SQLE (p=0.02). Oncogenic fusions involving NRG1, FGFR2, NTRK2 or BRAF were unique to KRAS wt tumors (67% of samples; p=1e-6). KRAS wt tumors showed expression patterns indicative of cholangiocytes and, when clustered alongside other tumor types, formed a distinct cluster with cholangiocarcinoma samples.
Conclusion
These data provide the first identification of distinct chr1q/chr8q amplification events unique to KRAS wt PDAC while highlighting novel and striking molecular similarities to cholangiocarcinoma. Taken together, results of the PanGen trial generate new hypotheses relevant to therapeutic targeting of KRAS wt PDAC and rationale towards incorporating KRAS mutation status as part of routine clinical testing in PDAC.
Citation Format: James Topham, Erica Tsang, Joanna Karasinska, Andrew Metcalfe, Hassan Ali, Steve Kalloger, Veronika Csizmok, Laura Williamson, Emma Titmuss, Hui-Li Wong, Richard Moore, Andrew Mungall, Jonathan Loree, Oliver Bathe, Patricia Tang, Rachel Goodwin, Janessa Laskin, Marco Marra, Steven Jones, David Schaeffer, Daniel Renouf. Analysis of KRAS wildtype pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB129.
Abstract LB192: Demethylation, DNA damage and antitumor activity of DNA methyltransferase inhibitors in models with intact and disrupted DNMT1 gene
Authors: Laranjeira Angelo B. , Hollingshead Melinda , Nguyen Dat , Kinders Robert , Difilippantonio Michael , Doroshow James H. , Yang Sherry X. 
Published: June 2022

Abstract
DNA methyltransferase (DNMT) 1 is an enzyme responsible for maintaining DNA methylation pattern during DNA replication. However, its role on the methylation of tumor suppressor genes and DNA damage in relation to antitumor activity of DNMT inhibitors remains controversial. Here, we investigated the effects of DNMT inhibitors in human colorectal and breast cancer cell lines and animal models with intact (DNMT1+/+) and disrupted DNMT1 (DNMT1-/-) gene. Treatment with 5 µM of 4’-thio-5-aza-2’-deoxycytidine (aza-TdC), decitabine and azacytidine all inhibited DNMT1 expression and cell growth (94.0%/97.1%, 39.9%/58.6% and 69.2/91.3), and induced apoptosis (66.9%/62.5%, 30.9%/23.8% and 66.2/43.1%) in DNMT1+/+ HCT116/MCF7 cells; in contrast, the DNMT inhibitors had less/little activities in DNMT1-/- HCT116/MCF7 cells (P&lt;0.001 each). γH2AX and G2/M cell-cycle arrest were induced by the inhibitors and greater degree of induction was produced by aza-TdC than decitabine in DNMT1+/+ cells (P&lt;0.001), with activation of checkpoint kinase 1 and upregulation of p21. Both demethylation and increased acetylation of CDKN2A and CDKN2B gene promoters together with re-expression of p16INK4A and p15INK4B proteins were detected in DNMT1-/- versusDNMT1+/+ (demethylation only) cells upon exposure to decitabine for 72h. Compared with saline treatment, tumor growth was significantly inhibited by aza-TdC (90%; n=18 mice) and decitabine (62%; n=18) in DNMT1+/+ colorectal xenograft tumors, alongside decreasing expression of DNMT1 (51% and 44%) and an increase in p21 (85% and 48%). Similarly, tumor growth delays (86%; n=15 and 57%; n=14) were associated with the reduction of DNMT1 and augmentation of p21 in bladder PDX tumors. The findings suggest that DNMT inhibitors induce DNA damage and higher anti-tumor activity of aza-TdC is proportional to a greater magnitude of induction of DNA damage, p21 and cell cycle arrest without reactivating the expression of p16INK4A and p15INK4B. The gene re-expression coupled to demethylation and acetylation corresponds to the less anti-tumor activity by decitabine in DNMT1-/- cells. Thus, it is the DNA damage effects, rather than re-expression of the tumor suppressors, that are associated with antitumor activity of the DNMT inhibitors in cancer cells and/or xenograft and PDX tumors.
Citation Format: Angelo B. Laranjeira, Melinda Hollingshead, Dat Nguyen, Robert Kinders, Michael Difilippantonio, James H. Doroshow, Sherry X. Yang. Demethylation, DNA damage and antitumor activity of DNA methyltransferase inhibitors in models with intact and disrupted DNMT1 gene [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB192.
Abstract LB203: Assessment of the safety, pharmacokinetics, and pharmacodynamics of a first-in-class cancer drug candidate E-602, a sialoglycan degrader, in non-human primates
Authors: Cao Lizhi , Che Jenny , Chesney Ali , Dixit Rakesh , Zheng Nancy , Zane Nicole , Broderick James , Peng Li 
Published: June 2022

Abstract
E-602 is a novel, first-in-class, engineered human sialidase (Neu2) Fc fusion developed for cancer treatment by enhancing antitumor immunity through desialylating immunosuppressive sialoglycans. We have previously shown that E-602 cleaves off terminal sialic acids from surface sialoglycans on tumor and immune cells, restores the immune function of exhausted-like T cells, and enhances dendritic cell priming and activation of naïve T cells. E-602 has also demonstrated antitumor activity as a single agent in multiple syngeneic mouse tumor models. To support clinical development, we conducted a Good Laboratory Practice one-month repeat-dose toxicity study to evaluate E-602’s pharmacokinetic (PK) parameters, pharmacodynamic (PD) effects, and safety profiles in cynomolgus monkeys via weekly intravenous infusion of E-602 at 5, 30, 100, and 200 mg/kg for five doses. E-602 showed an apparent half-life (t1/2) of 4-6 hours and the terminal t1/2 of 10-30 hours with dose linearity from 30 mg/kg to 200 mg/kg. E-602 produced dose-dependent PD effects of desialylation of immune cells, such as T cells, monocytes, and dendritic cells, as monitored by flow cytometry. Despite the short half-life of E-602, the PD effect of immune cell desialylation sustained up to seven days for T cells, consistent with E-602’s enzymatic mechanism of action. Generally, E-602 was well tolerated up to 100 mg/kg with no dose-limiting adverse E-602-related changes in body weight, ophthalmology, neurological/musculoskeletal assessments, electrocardiogram parameters, respiratory rate, coagulation, urinalysis, organ weights, and histopathology. Animals in the 200 mg/kg dose group survived but showed isolated adverse histopathological changes with an uncertain relationship to E-602 administration. Therefore, the no-observed-adverse-effect-level (NOAEL) of E-602 was determined as 100 mg/kg in cynomolgus monkeys. In conclusion, the PK and PD data have supported the selection of cynomolgus monkeys as the toxicity species to evaluate E-602’s safety profile. E-602 has demonstrated sustained PD effects of immune cell desialylation up to seven days postdose and a wide safety margin with NOAEL of 100 mg/kg in cynomolgus monkeys.
Citation Format: Lizhi Cao, Jenny Che, Ali Chesney, Rakesh Dixit, Nancy Zheng, Nicole Zane, James Broderick, Li Peng. Assessment of the safety, pharmacokinetics, and pharmacodynamics of a first-in-class cancer drug candidate E-602, a sialoglycan degrader, in non-human primates [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB203.